Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates

The Journal of Infectious Diseases
D E TaborAntonio DiGiandomenico

Abstract

Bispecific antibody MEDI3902, targeting the Pseudomonas aeruginosa type 3 secretion system (PcrV) and Psl exopolysaccharide, is currently in phase 2b development for prevention of nosocomial pneumonia in patients undergoing mechanical ventilation. We surveyed a diverse collection of isolates to study MEDI3902 epitope conservation and protective activity. P. aeruginosa clinical isolates (n = 913) were collected from diverse patients and geographic locations during 2003-2014. We conducted whole-genome sequencing; performed PcrV and Psl expression analyses via immunoblotting and enzyme-linked immunosorbent assay, respectively; performed crystallography to determine the MEDI3902 PcrV epitope, using anti-PcrV Fab and PcrV components (resolved at 2.8 Å); and evaluated MEDI3902 protective activity against select isolates in vitro and in vivo. Intact psl operon and pcrV genes were present in 94% and 99% of isolates, respectively, and 99.9% of isolates contained at least one of the genetic elements. Anti-Psl binding was confirmed in tested isolates harboring a complete Psl operon or lacking nonessential psl genes. We identified 46 PcrV variant sequences, and MEDI3902-PcrV contact residues were preserved. MEDI3902 maintained potent in vi...Continue Reading

References

Jun 29, 2002·The Journal of Infectious Diseases·Dara W FrankTeiji Sawa
Jul 3, 2004·Journal of Bacteriology·Masanori Matsukawa, E P Greenberg
Oct 21, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gerald B PierLisa Cavacini
Feb 3, 2005·Burns : Journal of the International Society for Burn Injuries·Alice N NeelyTeiji Sawa
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Antonio DiGiandomenicoJoanna B Goldberg
Aug 15, 2009·Nature Reviews. Microbiology·Alan R Hauser
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronald N Jones
Aug 10, 2010·American Journal of Respiratory and Critical Care Medicine·Mariano EsperattiAntoni Torres
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Nov 15, 2011·Critical Care Medicine·Ali A El-SolhHardik Vora
Jun 27, 2012·The Journal of Experimental Medicine·Antonio DiGiandomenicoC Kendall Stover
May 21, 2014·Antimicrobial Agents and Chemotherapy·Paul WarrenerC Kendall Stover
Nov 5, 2014·Antimicrobial Agents and Chemotherapy·Veronica N KosHumphrey Gardner
Nov 14, 2014·Science Translational Medicine·Antonio DiGiandomenicoC Kendall Stover
Nov 26, 2014·Genome Medicine·Michael InouyeKathryn E Holt
Aug 25, 2015·Current Opinion in Microbiology·Antonio DiGiandomenico, Bret R Sellman
Nov 21, 2015·Genome Announcements·Amine M BoukerbBenoit Cournoyer
Jul 19, 2016·Environmental Microbiology Reports·Philippe HuberIna Attrée
May 4, 2017·The Journal of Clinical Investigation·Ajitha ThanabalasuriarPaul Kubes
Nov 24, 2017·Scientific Reports·Valerie A RayAntonio DiGiandomenico

❮ Previous
Next ❯

Citations

Aug 27, 2019·F1000Research·Burkhard Tümmler
Apr 21, 2021·Antimicrobial Agents and Chemotherapy·Hanh N LamVictoria Auerbuch
Mar 14, 2020·Infectious Disorders Drug Targets·Gerard M RajMangaiarkkarasi Adhimoolam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.